Praxis Precision Medicines (PRAX) EBT Margin (2023 - 2024)
Praxis Precision Medicines (PRAX) posted quarterly EBT Margin of 3782.11% for Q4 2024, up 3666566.0% year-over-year from N/an in Q1 2024, and up 83.26% quarter-over-quarter from 22593.71% in Q3 2024.
Praxis Precision Medicines (PRAX) EBT Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' EBT Margin history runs 2 years deep, the most recent figure standing at 3782.11% for Q4 2024.
- In Q4 2024, EBT Margin rose 3666566.0% year-over-year to 3782.11%; the TTM figure through Sep 2025 stood at 7008.13% (up 1616277.0% YoY), while the FY2024 annual figure was 4892.65%, up 764875.0% from the prior year.
- EBT Margin for Q4 2024 stood at 3782.11%, up from 22593.71% in the prior quarter.
- The five-year high for EBT Margin was 3782.11% in Q4 2024, with the low at 40447.77% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.46 Bn | 131.61 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.04 Bn | 77.05 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.55 Bn | 59.36 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 59.56 Bn | 54.42 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.90 Bn | 36.80 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.69 Bn | 28.38 Bn | 992.69 Mn | 13.77% |
| 7 | Royalty Pharma | 27.45 Bn | 26.61 Bn | - | 12.09% |
| 8 | BioNTech SE | 27.40 Bn | 9.01 Bn | 668.28 Mn | -25.06% |
| 9 | Insmed | 26.70 Bn | 25.54 Bn | 358.27 Mn | -2.67% |
| 10 | Praxis Precision Medicines | 10.83 Bn | 10.07 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,782.11% |
| Sep 30, 2024 | -22,593.71% |
| Jun 30, 2024 | -11,001.12% |
| Mar 31, 2024 | -13,011.60% |
| Dec 31, 2023 | -40,447.77% |
| Sep 30, 2023 | -5,499.57% |
| Jun 30, 2023 | -4,482.59% |
| Mar 31, 2023 | -5,557.83% |